At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 16 enrolled
Drug / intervention
LY3316531 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Randomized, Placebo-Controlled Study to Determine the Effect of LY3316531 on Capsaicin-Induced Dermal Blood Flow in Healthy Male Subjects
In Brief
A Phase 1 clinical trial evaluating LY3316531 and Placebo for Healthy. Completed, enrolled 16 participants across 1 site.
Detailed Summary
The purpose of this study is to assess study drug activity by giving LY3316531 or placebo into a vein in the arm and then measuring blood flow of the skin, after capsaicin is applied to skin's surface. The study will last about 16 weeks inclusive of the screening period.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesBelgium
Collaborators--
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
First PostedAug 2018
Enrollment StartAug 2018
Primary CompletionMar 2019
TodayJul 2026
First PostedAug 2, 2018
Enrollment StartAug 30, 2018
Primary CompletionMar 15, 2019
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 7.9 years ago
Interventions
LY3316531drug
Administered IV
Placebodrug
Administered IV